<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    14688112
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     12
    </month>
    <day>
     22
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     02
    </month>
    <day>
     02
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0019-9567
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       72
      </volume>
      <issue>
       1
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        Jan
       </month>
      </pubdate>
     </journalissue>
     <title>
      Infection and immunity
     </title>
     <isoabbreviation>
      Infect. Immun.
     </isoabbreviation>
    </journal>
    <articletitle>
     Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.
    </articletitle>
    <pagination>
     <medlinepgn>
      332-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Asplenic individuals are known to be at increased risk of infection with encapsulated bacteria. Recent United Kingdom recommendations stated that this at-risk group should receive one dose of the meningococcal serogroup C conjugate (MCC) vaccine. However, the immune response of asplenic individuals to MCC vaccine is unknown. The immune response of asplenics (n = 130) to immunization with the MCC vaccine was investigated. Asplenic individuals had a significantly lower geometric mean titer (GMT) (157.8; 95% confidence interval [CI], 94.5 to 263.3) of bactericidal antibody in serum (SBA) than an age-matched control group (n = 48) (1448.2; 95% CI, 751.1 to 2792.0). However, 80% of asplenic individuals achieved the proposed protective SBA titer of &gt; or =8. No differences were observed between the two groups in the serogroup C-specific immunoglobulin G geometric mean concentration. A significant reduction in SBA GMT or the number of responders achieving an SBA titer of &gt; or =8 was observed if the reason for splenectomy was a medical cause or if MCC vaccination occurred &lt;10 years after splenectomy. Individuals (n = 29) who did not achieve an SBA titer of &gt; or =16 were offered a second dose of MCC vaccine. Analysis of the SBA response revealed that 61% (14 of 23) of the individuals who received a second dose achieved a protective titer. In total, 93% of asplenic individuals achieved a titer of &gt; or =8 following MCC vaccination (one or two doses combined). We recommend that, following vaccination of asplenics, either the level of functional antibody should be determined, with a second dose of MCC vaccine offered to nonresponders, or two doses of MCC vaccine should be routinely offered.
     </abstracttext>
    </abstract>
    <affiliation>
     Manchester Laboratory, Health Protection Agency North West, Manchester Medical Microbiology Partnership, Manchester M13 9WZ, United Kingdom. paul.balmer@hpa.org.uk
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Balmer
      </lastname>
      <forename>
       Paul
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Falconer
      </lastname>
      <forename>
       Michelle
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       McDonald
      </lastname>
      <forename>
       Paula
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Andrews
      </lastname>
      <forename>
       Nick
      </forename>
      <initials>
       N
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fuller
      </lastname>
      <forename>
       Emily
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Riley
      </lastname>
      <forename>
       Christine
      </forename>
      <initials>
       C
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kaczmarski
      </lastname>
      <forename>
       Edward
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Borrow
      </lastname>
      <forename>
       Raymond
      </forename>
      <initials>
       R
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Infect Immun
    </medlineta>
    <nlmuniqueid>
     0246127
    </nlmuniqueid>
    <issnlinking>
     0019-9567
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antibodies, Bacterial
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Immunoglobulin G
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Meningococcal Vaccines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      serogroup C meningococcal conjugate vaccine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Acta Paediatr Scand. 1982 May;71(3):451-5
     </refsource>
     <pmid version="1">
      7136661
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1980 Mar;141(3):404-12
     </refsource>
     <pmid version="1">
      6988526
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1993 May;167(5):1210-2
     </refsource>
     <pmid version="1">
      8486956
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1996 Jan;173(1):256-8
     </refsource>
     <pmid version="1">
      8537671
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1996 Feb 17;312(7028):430-4
     </refsource>
     <pmid version="1">
      8601117
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1996 Dec;174(6):1360-3
     </refsource>
     <pmid version="1">
      8940235
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1997 Jan;175(1):200-4
     </refsource>
     <pmid version="1">
      8985221
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Diagn Lab Immunol. 1997 Mar;4(2):156-67
     </refsource>
     <pmid version="1">
      9067649
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1998 Nov 18;280(19):1685-9
     </refsource>
     <pmid version="1">
      9832000
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1999 Feb;179(2):513-7
     </refsource>
     <pmid version="1">
      9878041
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 1999 Jun;179(6):1569-72
     </refsource>
     <pmid version="1">
      10228085
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 2000 Feb;181(2):761-4
     </refsource>
     <pmid version="1">
      10669372
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Infect Dis. 2001 Jan 1;183(1):160-3
     </refsource>
     <pmid version="1">
      11078484
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Infect Immun. 2001 Mar;69(3):1568-73
     </refsource>
     <pmid version="1">
      11179328
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Infect Immun. 2001 Apr;69(4):2378-82
     </refsource>
     <pmid version="1">
      11254596
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Vaccine. 2001 Apr 30;19(23-24):3043-50
     </refsource>
     <pmid version="1">
      11311998
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Infect Immun. 2001 Dec;69(12):7583-7
     </refsource>
     <pmid version="1">
      11705936
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Microbiol Infect. 2001 Dec;7(12):657-60
     </refsource>
     <pmid version="1">
      11843905
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Clin Invest. 1975 Dec;56(6):1536-47
     </refsource>
     <pmid version="1">
      1202084
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Pediatr Infect Dis J. 2002 Oct;21(10):978-9
     </refsource>
     <pmid version="1">
      12400528
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Med. 2002 Sep-Oct;2(5):440-3
     </refsource>
     <pmid version="1">
      12448592
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 2003 Feb 15;326(7385):365-6
     </refsource>
     <pmid version="1">
      12586669
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Exp Med. 2003 Apr 7;197(7):939-45
     </refsource>
     <pmid version="1">
      12682112
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Diagn Lab Immunol. 2003 Sep;10(5):780-6
     </refsource>
     <pmid version="1">
      12965904
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Scand J Infect Dis. 1992;24(5):629-32
     </refsource>
     <pmid version="1">
      1465581
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Hematol. 1977;2(2):193-201
     </refsource>
     <pmid version="1">
      329670
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1967 Jun 1;276(22):1225-9
     </refsource>
     <pmid version="1">
      6024340
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Clin Microbiol. 1994 Jun;32(6):1475-82
     </refsource>
     <pmid version="1">
      8077392
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antibodies, Bacterial
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Blood Bactericidal Activity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunoglobulin G
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Meningococcal Infections
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Meningococcal Vaccines
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Neisseria meningitidis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Splenectomy
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC343978
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      12
     </month>
     <day>
      23
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      2
     </month>
     <day>
      3
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      12
     </month>
     <day>
      23
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     14688112
    </articleid>
    <articleid idtype="pmc">
     PMC343978
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

